Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CPI-1189. Centaur.

Thomas Müller1

  • 1Department of Neurology, St Josef Hospital, Ruhr University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de

Current Opinion in Investigational Drugs (London, England : 2000)
|January 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stereo- and regioselective phyllobilane oxidation in leaf homogenates of the peace lily (Spathiphyllum wallisii): hypothetical endogenous path to yellow chlorophyll catabolites.

Chemistry (Weinheim an der Bergstrasse, Germany)·2014
Same author

Stereo- and regioselective phyllobilane oxidation in leaf homogenates of the peace lily (Spathiphyllum wallisii): hypothetical endogenous path to yellow chlorophyll catabolites.

Chemistry (Weinheim an der Bergstrasse, Germany)·2014
Same author

Stereo- and Regioselective Phyllobilane Oxidation in Leaf Homogenates of the Peace Lily (Spathiphyllum wallisii): Hypothetical Endogenous Path to Yellow Chlorophyll Catabolites.

Chemistry (Weinheim an der Bergstrasse, Germany)·2014
Same author

["Every single assault prevented is worth the effort"].

MMW Fortschritte der Medizin·2014
Same author

Endocavitary contrast-enhanced ultrasound: a technique whose time has come?

Journal of clinical ultrasound : JCU·2014
Same author

Efficiency of gas transfer in venovenous extracorporeal membrane oxygenation: analysis of 317 cases with four different ECMO systems.

Intensive care medicine·2014

The compound CPI-1189 effectively treats neurodegenerative diseases by inhibiting tumor necrosis factor (TNF) alpha and protecting brain cells. Clinical trials show it improves cognitive and motor functions in Parkinson

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Chronic neurodegenerative and inflammatory diseases involve proapoptotic cytokine tumor necrosis factor (TNF) alpha.
  • Intracellular inhibition of p38 mitogen-activated protein kinase (MAPK) phosphoactivation offers neuroprotection.
  • CPI-1189 is a compound that inhibits TNF alpha and p38 MAPK.

Purpose of the Study:

  • To evaluate the efficacy and clinical relevance of CPI-1189 in treating neurodegenerative diseases.
  • To assess the safety and side effect profile of CPI-1189 in human trials.
  • To explore CPI-1189 as a potential long-term therapeutic alternative for neuroprotection.

Main Methods:

  • Demonstrated efficacy in cell culture and animal models.
  • Conducted clinical proof-of-concept phase IIa trials in patients with Parkinson's disease and AIDS dementia complex.

Related Experiment Videos

  • Administered CPI-1189 at doses of 50 to 100 mg/day.

    • Main Results:

    • CPI-1189 successfully attenuated cognitive and/or motor function deterioration.
    • No relevant side effects were observed during clinical trials.
    • Positive clinical proof-of-concept was established for CPI-1189 treatment.

    Conclusions:

    • CPI-1189 shows clinical relevance for treating neurodegenerative conditions like Parkinson's disease and AIDS dementia complex.
    • Long-term application of CPI-1189 is a promising therapeutic alternative for neuroprotection.
    • CPI-1189 offers a potential treatment strategy by targeting immunological pro-apoptotic alterations in the central nervous system.